LRRK2 and Parkinson disease: In several PD models, luteolin has been reported to act by inhibiting the release of and/or decreasing the levels and activity of lactate dehydrogenase, caspase-3, IL-1β, TNF-α, and reducing mRNA levels of Lrrk2 [108, 109].